Loxo, Bayer get first FDA win with $400k rare cancer drug

Nov 29, 2018

A cutting-edge oncology drug developed by Loxo Oncology and Bayer has won approval in the U.S. 

Unlike medications that target a specific cancer, Loxo’s drug, Vitravki, is designed to treat a specific “TRK gene fusion” mutation, and was shown effective for treating a number of different cancers. The FDA approved Vitravki for adults and children with advanced solid tumors, and is one of the first drugs to get a regulatory nod for a tumor-agnostic indication. 

Vitravki is the first medication by Loxo to win regulatory approval and comes with a $32,800-per month price tag. 

The specific mutation only affects about 3,000 Americans every year, but some analysts have forecasted that sales for the drug could reach $1 billion by 2024. 

Loxo is also developing another drug that treats a different rare gene mutation called RET, which can be present in patients with lung, thyroid and other cancers. 

Read the full Reuters report.

Want to get news like this in your inbox?  Subscribe to our eNewsletter here!

Show Comments
Hide Comments

Join the discussion

We welcome your thoughtful comments.
All comments will display your user name.

Want to participate in the discussion?

Register for free

Log in for complete access.


No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments